Combivir (lamivudine;zidovudine)
- Region
- 🇪🇺 EU
- Active substance
- lamivudine;zidovudine
- Company
- ViiV Healthcare BV
- Status
- Authorised
- Therapeutic area
- HIV Infections
- CHMP opinion
- Wed 19 Nov 1997
- EU approval
- Wed 18 Mar 1998
- Application
- EMEA/H/C/000190
- ATC
- J05AR01
- Official record
- www.ema.europa.eu
Indication
Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Trizivir Withdrawn · ViiV Healthcare BV
- 🇪🇺 Lamivudine/Zidovudine Teva Withdrawn · Teva Pharma B.V.
Follow Combivir
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.